Literature DB >> 9764129

Pharmacotherapy of first-episode schizophrenia.

G Remington1, S Kapur, R B Zipursky.   

Abstract

BACKGROUND: A growing interest in first-episode schizophrenia reflects the belief that this line of investigation will lead to further developments regarding schizophrenia's aetiology, course and outcome.
METHOD: Evidence from more recent clinical trials involving first-episode schizophrenia is integrated with neuroimaging data, specifically positron emission tomography, to provide direction regarding pharmacotherapy.
RESULTS: Individuals with a first episode of schizophrenia appear particularly responsive to pharmacotherapy, as well as quite sensitive to side-effects. At the same time, current clinical and receptor-binding data support the efficacy of low-dose neuroleptic treatment.
CONCLUSIONS: Early and effective treatment of schizophrenia has been associated with better long-term outcome. Low-dose neuroleptic therapy is an effective treatment strategy and the diminished risk of side-effects with this approach may further enhance compliance and outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764129

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  9 in total

1.  Atypical antipsychotics in the treatment of schizophrenia. Users' experiences of treatments must be considered.

Authors:  C Prior ; J Clements; M Rowett
Journal:  BMJ       Date:  2001-04-14

Review 2.  Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies.

Authors:  J Tauscher; S Kapur
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

4.  Challenges associated with application of clinical staging models to psychotic disorders.

Authors:  Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2011-10-01       Impact factor: 13.382

5.  The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Authors:  Dieter Naber; Martin Lambert
Journal:  CNS Drugs       Date:  2009-08       Impact factor: 5.749

6.  Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.

Authors:  Patrick D McGorry; John Cocks; Paddy Power; Peter Burnett; Susy Harrigan; Tim Lambert
Journal:  Schizophr Res Treatment       Date:  2011-02-07

7.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis.

Authors:  Daniela Polese; Michele Fornaro; Mario Palermo; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

8.  Psychopathology and treatment responsiveness of patients with first-episode schizophrenia.

Authors:  Eva Cesková; Radovan Prikryl; Tomás Kaspárek; Marta Ondrusová
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

9.  Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender.

Authors:  Debra L Foley; Andrew Mackinnon; Gerald F Watts; Jonathan E Shaw; Dianna J Magliano; David J Castle; John J McGrath; Anna Waterreus; Vera A Morgan; Cherrie A Galletly
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.